Transdermal Delivery of Sumatriptan for the Treatment of Acute Migraine

Pierce, Mark

doi:10.1016/j.nurt.2010.03.005

Cited by 31 publications

(21 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of a randomized, double-blind, placebo-controlled Phase III trial of sumatriptan TDS for the acute treatment of migraine has been reported [21][22][23][24]. This trial recruited 530 adults, with a diagnosis of migraine according to International Classification of Headache Disorders-II criteria.…”

Section: Overview Of Clinical Trialsmentioning

confidence: 99%

See 1 more Smart Citation

Sumatriptan Iontophoretic Transdermal System for the Acute Treatment of Migraine

2014

View full text Add to dashboard Cite

SUMMARY We will describe the pharmacokinetic profile, clinical efficacy and safety data of the sumatriptan iontophoretic transdermal system (Zecuity®, NuPathe Inc., PA, USA), recently approved for the acute treatment of migraine with or without aura in adults, by the US FDA. This transdermal system utilizes a low-level electrical current to deliver sumatriptan transdermally and circumvents the GI tract. Pharmacokinetic studies have shown that iontophoretic delivery of sumatriptan achieves detectable plasma concentrations 15 min after activation with a maximum mean serum concentration of 22 ng/ml. A randomized, double-blind, controlled clinical trial demonstrated minimal triptan-related side effects and superior efficacy versus placebo. The pain-free rate at 2 h postdose was 18% of patients applying the sumatriptan patch versus 9% using the placebo (p = 0.0092). This sumatriptan transdermal system may be a good choice for migraineurs with severe nausea or vomiting, those with intolerable triptan-related adverse events and/or those not responding optimally to oral medications.

show abstract

Section: Overview Of Clinical Trialsmentioning

confidence: 99%

“…Virtually no triptan-related AEs were reported. Withdrawal from the study due to AEs was low in both treatment groups 2.1% for sumatriptan TDS and 1.3% for placebo [21][22][23][24].…”

Section: Adverse Reactionsmentioning

confidence: 99%

Sumatriptan Iontophoretic Transdermal System for the Acute Treatment of Migraine

2014

View full text Add to dashboard Cite

show abstract

“…Transdermal delivery represents a non‐oral treatment alternative that, until recently, has not been attempted in migraine . Well‐established in other disease states, this route of administration has a range of benefits that includes avoidance of the gastrointestinal (GI) tract and first‐pass metabolism, sustained and controlled delivery, and convenient usage .…”

Section: Transdermal Delivery Of Sumatriptan: From Concept To Clinicamentioning

confidence: 99%

Sumatriptan Iontophoretic Transdermal System: History, Study Results, and Use in Clinical Practice

et al. 2013

View full text Add to dashboard Cite

Nausea is a common symptom of migraine, and current treatment guidelines recommend non-oral formulations for nauseated or vomiting patients. Transdermal delivery of sumatriptan, a 5-hydroxytryptamine1B1D agonist with established efficacy in patients with migraine, represents a novel approach to acute treatment. The sumatriptan iontophoretic transdermal system circumvents the gastrointestinal tract by using low-level electrical energy to transport sumatriptan across the skin. In multiple well-controlled studies, the sumatriptan transdermal system has shown that it provides consistent drug delivery with low interpatient variability, rapid relief of migraine pain and associated symptoms, and an excellent overall safety profile, with a low incidence of triptan-sensation adverse events. Patients and health care professionals who have used the sumatriptan transdermal system give it high ratings for ease of use/application. The sumatriptan transdermal system will allow a wide range of patients, especially those who experience migraine-related nausea or vomiting, to receive the benefits of migraine-specific therapy.Key words: migraine, treatment, sumatriptan, transdermal, gastrointestinal, nausea (Headache 2013;53;S2:34-42) Migraine is a chronic neurologic disorder that affects about 28 million people in the United States 1 with episodic attacks of head pain and some combination of photophobia, phonophobia, nausea, and/or vomiting.2 Although migraine frequency, intensity, and symptomatology tend to vary over time, evidence suggests that about half (49.5%) of patients have migraine-related nausea (MRN) with at least half of their attacks.3 In addition to being a common feature of migraine, frequent MRN has been shown to increase migraine symptom burden and medicationrelated impairment at home, work, and school, as well as in social and leisure activities, 4 and satisfaction with treatment decreases as the frequency of MRN increases.3

show abstract

“…A needle-free delivery of injectable sumatriptan was approved in the USA by the US FDA in July 2009 for individuals with needle phobia [102]. Phase III clinical trials with a transdermal patch, known as Zelrix, have been underway since April 2010 [21].…”

Section: Overview Of the Marketmentioning

confidence: 99%

Triptan Use In Pediatric Migraine: Focus on Rizatriptan

Kacperski

O’Brien

2012

Future Neurol.

View full text Add to dashboard Cite

Migraines are a common complaint in children and can cause a significant burden to both the child and their families, with a substantial loss in both school and work days, as well as having negative effects on the child’s self-esteem and peer relations. It has become clear that migraine-specific medications are needed in this population of patients and their use may result in a significant improvement of the child’s headaches and quality of life. Rizatriptan benzoate (Maxalt®) is a selective 5-hydroxytryptamine/serotonin1B/1D (5-HT1B/1D ) agonist that was approved by the US FDA in 1998 for the acute treatment of migraine attacks in adults. Despite having been widely used in the pediatric population, rizatriptan was most recently approved in December 2011 for pediatric use in children aged 6–17 years. The advantage of rizatriptan over some other triptans is its rapid onset of action, which is thought to be beneficial in the generally shorter migraine attacks of children when compared with adults. It may also be an appealing choice for young children because it comes in an orally disintegrating form for those who may have difficulty in swallowing tablets or who have significant gastrointestinal complaints accompanying their headaches, including nausea, vomiting and abdominal pain.

show abstract

Transdermal Delivery of Sumatriptan for the Treatment of Acute Migraine

Cited by 31 publications

References 18 publications

Sumatriptan Iontophoretic Transdermal System for the Acute Treatment of Migraine

Sumatriptan Iontophoretic Transdermal System for the Acute Treatment of Migraine

Sumatriptan Iontophoretic Transdermal System: History, Study Results, and Use in Clinical Practice

Triptan Use In Pediatric Migraine: Focus on Rizatriptan

Contact Info

Product

Resources

About